A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder
- PMID: 37404966
- PMCID: PMC10316220
- DOI: 10.1176/appi.focus.20220088
A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder
Erratum in
-
Correction to Lewis, et al. (2023).Focus (Am Psychiatr Publ). 2025 Jan;23(1):67. doi: 10.1176/appi.focus.20220088correction. Epub 2024 Dec 13. Focus (Am Psychiatr Publ). 2025. PMID: 39776460 Free PMC article.
Abstract
Posttraumatic stress disorder (PTSD) is a common chronic and disabling psychiatric disorder that may develop after exposure to a traumatic life event. There are existing evidence-based psychotherapies and pharmacotherapies for PTSD; however, these treatments have significant limitations. 3,4-methylenedioxymethamphetamine (MDMA) was granted "breakthrough therapy" status by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of PTSD in conjunction with psychotherapy after preliminary Phase II results. This treatment is currently being investigated in Phase III trials with anticipated FDA approval of MDMA-assisted psychotherapy for PTSD in late 2023. This article reviews the evidence base for MDMA-assisted psychotherapy for PTSD, pharmacology and the proposed causal mechanisms of MDMA, risks and limitations of the current evidence, and challenges and future directions for the field.
Keywords: Posttraumatic Stress Disorder; Psychotherapy; Trauma and stress-related disorder.
Copyright © 2023 by the American Psychiatric Association.
Conflict of interest statement
The authors report no financial relationships with commercial interests.
Similar articles
-
MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward.CNS Drugs. 2025 Apr;39(4):339-343. doi: 10.1007/s40263-025-01162-y. Epub 2025 Feb 15. CNS Drugs. 2025. PMID: 39955464
-
3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review.Cureus. 2022 Jun 28;14(6):e26402. doi: 10.7759/cureus.26402. eCollection 2022 Jun. Cureus. 2022. PMID: 35915689 Free PMC article. Review.
-
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.J Psychopharmacol. 2018 Dec;32(12):1295-1307. doi: 10.1177/0269881118806297. Epub 2018 Oct 29. J Psychopharmacol. 2018. PMID: 30371148 Free PMC article. Clinical Trial.
-
Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.Focus (Am Psychiatr Publ). 2023 Jul;21(3):306-314. doi: 10.1176/appi.focus.23021013. Epub 2023 Jun 28. Focus (Am Psychiatr Publ). 2023. PMID: 37404974 Free PMC article. Review.
-
Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.Front Psychiatry. 2019 Sep 12;10:650. doi: 10.3389/fpsyt.2019.00650. eCollection 2019. Front Psychiatry. 2019. PMID: 31572236 Free PMC article. Review.
References
-
- Cloitre M , Hyland P , Bisson JI , et al. : ICD-11 posttraumatic stress disorder and complex posttraumatic stress disorder in the United States: a population-based study . J Trauma Stress 2019. ; 32 : 833 – 842 - PubMed
-
- Diagnostic and Statistical Manual of Mental Disorders , 5th ed. , Text Revision . Washington, DC: , American Psychiatric Association Publishing; , 2022. , pp. 302 – 314
-
- Dekel S , Gilbertson MW , Orr SP , et al. : Trauma and posttraumatic stress disorder ; in Massachusetts General Hospital Comprehensive Clinical Psychiatry , 2nd ed . Philadelphia: , Elsevier; , 2016.
-
- Norris FH , Slone LB : The epidemiology of trauma and PTSD ; in Handbook of PTSD: Science and Practice . Edited by Friedman MJ , Keane TM , Resick PA . New York: , Guilford Press; , 2007.
Publication types
LinkOut - more resources
Full Text Sources